|
|
TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock
|
|
|
TherapeuticsMD Announces Participation in the Stifel 2020 Virtual Healthcare Conference
|
|
|
TherapeuticsMD Announces Pricing of $30 Million Public Offering of Common Stock
|
|
|
TherapeuticsMD Announces Underwritten Public Offering of its Common Stock
|
|
|
TherapeuticsMD® Announces Third Quarter 2020 Financial Results
|
|
|
TherapeuticsMD to Report Third Quarter 2020 Results on November 9, 2020
|
|
|
POPSUGAR Launches New Women’s Health Destination, “Full Disclosure,” in Collaboration With TherapeuticsMD
|
|
|
TherapeuticsMD Supports the Importance of Empowering Women to Make Informed Choices about their Sexual and Reproductive Health
|
|
|
TherapeuticsMD Provides Update on Third Quarter Progress
|
|
|
Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®
|
|
|
TherapeuticsMD Announces Participation at Two Upcoming Virtual Investor Conferences
|
|
|
TherapeuticsMD Announces Patent Updates for ANNOVERA®
|
|
|
Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®
|
|
|
TherapeuticsMD® Announces Second Quarter 2020 Financial Results
|
|
|
TherapeuticsMD to Report Second Quarter 2020 Results on August 6, 2020
|
|
|
TherapeuticsMD and Nurx Expand Access to ANNOVERA®
|
|
|
TherapeuticsMD Announces Appointment of James C. D’Arecca as Chief Financial Officer and Retirement of Daniel A. Cartwright as Chief Financial Officer
|
|
|
TherapeuticsMD Announces Participation at the BofA Securities 2020 Health Care Conference
|
|
|
TherapeuticsMD Announces First Quarter 2020 Financial Results
|
|
|
TherapeuticsMD Announces Issuance of First Orange Book Listable U.S. Patent for ANNOVERA®
|
|
|
TherapeuticsMD to Report First Quarter 2020 Results on May 6, 2020
|
|
|
TherapeuticsMD Further Strengthens Board with Appointment of New Independent Director
|
|
|
TherapeuticsMD Provides COVID-19-Related Business Update
|
|
|
TherapeuticsMD Strengthens Board with Appointment of Industry Leaders
|
|
|
TherapeuticsMD Provides Business Update on COVID-19 Pandemic
|
|
|
TherapeuticsMD Announces Participation at the Cowen 40th Annual Healthcare Conference
|
|
|
TherapeuticsMD Announces Fourth Quarter and Full-Year 2019 Financial Results
|
|
|
TherapeuticsMD and Afaxys Enter Into Agreement to Expand Access to ANNOVERA® in the U.S. Public Health Sector
|
|
|
TherapeuticsMD to Report Fourth Quarter 2019 Results on February 20, 2020
|
|
|
TherapeuticsMD Announces Submission of New Drug Application Prior Approval Efficacy Supplement to the U.S. Food and Drug Administration for Lower Dose of BIJUVA®
|
|
|
TherapeuticsMD, an Innovative Women’s Healthcare Company, and PlushCare, a Virtual Health Platform, Announce Enhanced Access to Women’s Health Products
|
|
|
TherapeuticsMD Announces Participation at the JP Morgan Healthcare Conference
|
